Clinical Trials Logo

Non-communicable Disease clinical trials

View clinical trials related to Non-communicable Disease.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06311162 Not yet recruiting - Asthma in Children Clinical Trials

Early Life Intervention in Pediatrics Supported by E-health - SMOKE

ELIPSE-II
Start date: March 31, 2024
Phase: N/A
Study type: Interventional

Unrestricted parental smoking habits are lifestyle risk behaviors associated with chronic, systemic inflammation, which promotes the pathogenesis of non-communicable diseases (NCDs). Exposure to secondhand tobacco smoke in early life contributes to the development of specific NCDs in children, i.e. asthma. Early preventive measures to improve lifestyle behavior in parents are therefore of utmost importance. The aim of ELIPSE-II is to assess whether an eHealth application intervention for parents is feasible and efficacious in lowering levels of urinary cotinine as a measure of second-hand smoke exposure in their children .

NCT ID: NCT06191302 Not yet recruiting - COVID-19 Clinical Trials

Post-acute COVID-19 Sequelae in Denmark

Start date: February 1, 2024
Phase:
Study type: Observational [Patient Registry]

Since the first SARS-CoV-2 cases in 2019, over 660 million COVID-19 cases have been reported globally, including 183 million in the EU. Up to 70% of those infected experience reduced organ function four months or more after a COVID-19 diagnosis, potentially increasing the risk of non-communicable diseases (NCDs). The post-acute phase (PAP) after COVID-19 (four months or more after the acute phase) can lead to impaired function in various organ systems, with a focus on the lungs, cardiovascular system, and kidneys. These three NCDs collectively impose a significant burden on individuals and society. Urgently, we need to understand the connection between COVID-19's PAP and NCDs, identifying robust biomarkers for early detection. This study examines PAP and associated risk factors, investigating the link between PAP and the heightened risk of lung, heart, and kidney complications. Utilizing data from a cohort of COVID-19 patients and a control group with respiratory diseases, the study aims to determine prevalence and risk ratios more precisely. The aim is to contribute to minimizing the risk of NCD development or exacerbation in current and future COVID-19 patients, enhancing our understanding of chronic disease development at the population leve

NCT ID: NCT06074939 Not yet recruiting - Tobacco Use Clinical Trials

FRESHAIR4Life: Building the Case for Action

Start date: October 2023
Phase:
Study type: Observational

The goal of this observational study is to understand the burden and determinants of tobacco use and air pollution (AP) exposure among mid- to late adolescents in Greece, the Kyrgyz Republic, Pakistan, Romania, and Uganda. This context-specific knowledge will be crucial for selecting, adapting, and implementing preventive interventions in the next phase of the project. The main questions the investigators aim to answer are: - What is the perceived burden of tobacco use and AP exposure among adolescents? - What are the contextual drivers and behavioral determinants contributing to (prevention of) these risk factors? - How do the dynamics between stakeholders influence prevention efforts? In this study, data will be collected through interviews, focus group discussions, photovoice, document analysis, observations, personal exposure monitoring, and questionnaires.